Jazz Pharmaceuticals

Jazz received US approval of Ziihera as a first-line treatment of all HER2-positive advanced gastroesophageal adenocarcinoma, or GEA, used in addition to chemotherapy, with or without Tevimbra. Additional phase 3 data further reinforced its survival advantage over Herceptin with longer follow-up.

Why it matters: Originally approved in November 2024 for previously treated advanced HER2‑positive biliary tract cancer, Ziihera combinations demonstrated statistically significant and clinically meaningful improvements in overall survival benefit, reducing the risk of death by 28% compared with Herceptin and chemotherapy, which has been the current standard of care. We project Ziihera will evolve from a niche BTC asset, which generated $25 million in 2025, into a significant oncology growth platform following its GEA approval and potential expansion into multiple HER2-driven cancers. Given Ziihera's strong clinical profile, we think it will become the new GEA standard of care and forecast annual Ziihera sales exceeding $1 billion by 2030. Jazz is evaluating Ziihera across multiple breast cancer studies, and we view a potential data readout in late-2027 for previously treated metastatic breast cancer as the franchise's most important catalyst, given its potential to validate the drug in a substantially larger patient population.

The bottom line: We raised our fair value estimate to $225 per share from $196 for no-moat Jazz based on stronger sales for Ziihera and improved near-term outlook for the firm. We forecast a five-year compound annual growth rate of about 8%, supported by strong uptake and commercial success for Jazz's newly launched assets. Still, shares trade 11% above our valuation. A positive readout in breast cancer would extend Ziihera's growth trajectory and increase confidence in Jazz's long-term $3 billion to $5 billion peak Ziihera sales ambitions. We anticipate Ziihera could potentially launch in HER2-positive metastatic breast cancer by early 2029.

BLANK PAGE

We have raised our fair value estimate to $225 per share from $196 for no-moat Jazz based on stronger sales for Ziihera and improved near-term outlook for the firm.

We have a positive outlook for Ziihera, and it received US approval as a first-line treatment of all HER2-positive advanced gastroesophageal adenocarcinoma used in addition to chemotherapy, with or without Tevimbra. Ziihera combinations have demonstrated statistically significant and clinically meaningful improvements in overall survival benefit, reducing the risk of death by 28% compared with Roche's Herceptin and chemotherapy, which has been the current standard of care.

We project Ziihera will evolve from a niche asset for HER2‑positive biliary tract cancer, which generated $25 million in 2025, into a significant oncology growth platform following its GEA approval and potential expansion into multiple HER2-driven cancers. Given Ziihera's strong clinical profile, we think it will become the new GEA standard of care and forecast annual Ziihera sales exceeding $1 billion by 2030.

Jazz is evaluating Ziihera across multiple breast cancer studies, and we view a potential data readout in late-2027 for previously treated metastatic breast cancer as the franchise's most important catalyst, given its potential to validate the drug in a substantially larger patient population. A positive readout in breast cancer would extend Ziihera's growth trajectory and increase confidence in Jazz's long-term $3 to $5 billion peak Ziihera sales ambitions. We anticipate Ziihera could potentially launch in HER2-positive metastatic breast cancer by early 2029.

Xywav (for excessive daytime sleepiness) and Epidiolex (for childhood epilepsy) have continued to be Jazz’s primary growth drivers thanks to their commercial success that has seen strong prescriber and patient adoption. Epidiolex reached blockbuster status at just over $1 billion in annual sales in 2025. Epidiolex has strong efficacy and has benefited from robust launches in the US and Europe.

Generic Xyrem launched in January 2023, but we think Jazz's agreement with Hikma to receive royalties from authorized Xyrem generics will slightly offset the declines. Management believes Xywav, a low-sodium version of Xyrem, will result in a significant number of Xyrem patients switching to this next-generation version of the drug and help preserve its profits. Xywav has already achieved market-leading adoption in narcolepsy and increased patient adoption in idiopathic hypersomnia. However, we anticipate the low-sodium version will modestly offset Xyrem's declines as a subset of patients will feel compelled to switch medications. Generic entry of Xyrem will still put pressure on Jazz and make it harder for the company to command pricing power. Plus, there is competition from other branded therapies such as Alkermes' Lumryz and Harmony Biosciences' Wakix, which could weaken Jazz’s revenue growth due to their once-nightly and once-daily administration, respectively, as opposed to Xywav's twice-nightly regimen.

We do not believe Jazz possesses an economic moat, given its reliance on its core sleep franchise. Xyrem, once Jazz's flagship narcolepsy drug, has been rendered largely immaterial by generic erosion following the loss of its patent exclusivity. The oxybate franchise has migrated almost entirely to Xywav, which now faces its own competitive threats from newly approved high-sodium generic oxybates and branded competition from Alkermes' Lumryz. Xyrem's historically strong sales allowed Jazz to invest both organically and inorganically to diversify its portfolio, and the clearest early payoff is Ziihera, a bispecific HER2-directed antibody that has already secured accelerated approval in biliary tract cancer and full approval in gastroesophageal adenocarcinoma, with management targeting $3 billion-$5 billion in peak sales potential across its expanding label. Management has also worked to broaden the portfolio with the approvals of Zepzelca, Rylaze, and Modeyso. Continued strong launches and commercialization efforts for these drugs will be crucial for Jazz to further expand its portfolio beyond its sleep franchise.

We agree with management's assessment that Jazz's core oxybate franchise lacks durable competitive protection. Branded and generic competition is eroding Xywav, and multiple portfolio drugs face patent expirations through the early 2030s. Together, these factors lead us to a no-moat rating for Jazz.

We think the clearest path to a narrow-moat upgrade could run through Ziihera. Positive phase 3 breast cancer data (expected in late 2027) and subsequent approval potentially in 2029 could meaningfully expand Ziihera's addressable population beyond its current biliary tract cancer and gastroesophageal adenocarcinoma indications. However, the treatment landscape for HER2-positive breast cancer is competitive, and we would need to see Ziihera achieve durable market share before assigning a moat.

Jazz added Xyrem to its portfolio in 2005 with the acquisition of Orphan Medical. At that point, Xyrem was the only approved treatment for cataplexy in narcolepsy; it has since garnered additional approvals for excessive daytime sleepiness in patients with narcolepsy. Xyrem supported strong returns for Jazz for over a decade due to its unmatched efficacy and lack of direct competition prior to generic entry. Jazz continues to earn royalties on authorized-generic oxybate sales through its shared distribution program, though this royalty stream is on a declining trajectory as more branded and generic alternatives enter the market, underscoring the terminal trend of the legacy Xyrem franchise.

Using its development expertise from Xyrem, Jazz developed and received FDA approval for Xywav, which contains 92% less sodium than Xyrem. Xywav was approved by the FDA in July 2020 and launched in the US in November 2020 for the treatment of cataplexy or EDS in narcolepsy patients 7 years and older. Xywav also received FDA approval in August 2021 for the treatment of adults with idiopathic hypersomnia and launched in the US in November 2021.

Management believes Xywav will result in a significant number of Xyrem patients switching to this next-generation version of the drug and help preserve its profits. We anticipate the low-sodium version will help offset Xyrem's declines as a subset of patients will feel compelled to switch medications. However, our forecast also accounts for alternative drugs hitting the market, including generics of Xyrem that launched in January 2023. Alkermes' drug, Lumryz, received approval from the FDA in May 2023 as a once-nightly treatment of EDS or cataplexy in adults with narcolepsy. We think Lumryz will weaken Xywav’s revenue groawth with its once-nightly administration as opposed to Xywav’s twice-nightly regimen. We also continue to anticipate that pricing pressure from the generic version of Xyrem will result in reduced pricing power for Xywav, payer reimbursement decisions will hurt sales growth, and some patent losses associated with Xyrem will affect Xywav.

Vyxeos, approved in August 2017, had a strong launch in acute myeloid leukemia, but sales growth has significantly slowed as the field has become highly competitive with new drug approvals, including Roche and AbbVie's Venclexta and Pfizer's Daurismo, which are approved for a broader proportion of AML patients than Vyxeos. Vyxeos has six US patents expiring between April 2025 and April 2029.

We see the strategic rationale for Jazz’s 2021 acquisition of GW Pharmaceuticals and its leading drug, Epidiolex, which had already received US approval and was marketed in Europe. It achieved a blockbuster status of over $1 billion in sales in 2025. This acquisition allows Jazz to reach patient populations with rare and severe forms of epilepsy with approved indications for Epidiolex as young as 1 year of age. While the patient population is small for rare diseases, there are limited therapeutic options available, and Epidiolex has strong efficacy with a median reduction in seizures of 43.9% versus 21.8% for a placebo.

While Jazz has been working to diversify its portfolio with its oncology drugs Zepzelca, Modeyso, and Ziihera, we see continued risk from oxybate competition and staggered patent losses across the portfolio through the early 2030s. We’ve assigned Jazz a High Uncertainty Rating to reflect this risk, and we do not currently have confidence in assigning Jazz an economic moat.

The GW acquisition allows Jazz to reach patient populations with rare and severe forms of epilepsy with approved indications for Epidiolex as young as 1 year of age.

Jazz's extensive network of sleep doctors should give the company a competitive edge when marketing its new sleep therapies.

Xyrem's historically strong cash generation has allowed the company to make recent acquisitions to help diversify its portfolio.

Jazz will face branded competition from Wakix and Lumryz, in addition to generic pressure, which will likely erode Jazz's patient share.

It will be more difficult for Jazz to command pricing power with competition from generic Xyrem.

Failure of key pipeline assets or delays in clinical development could leave Jazz with limited growth drivers, making it difficult to offset maturing products and maintain long-term revenue growth.